Vincogen is focusing on the new and niche markets, gastrointestinal diseases and personalized medicine, with superior technology that outruns the competitors.  Significantly, the company’s patented display and delivery system is beyond the development stage. It is currently being used for applications such as:

 

New emerging diseases/pathogens medicine

Infectious diseases remain among the leading causes of death worldwide in 20th century for three reasons: 1) emergence of new infectious diseases; 2) re-emergence of old infectious diseases; and 3) persistence of intractable infectious diseases. Emerging diseases include outbreaks of previously unknown diseases or known diseases whose incidence in humans has significantly increased. Recently, advanced research and diagnostic methods have revealed a number of previously unknown human pathogens. For example, within the last decade, chronic gastric ulcers, which were formerly thought to be caused by stress or diet, were found to be the result of infection by the bacterium Helicobacter pylori. (NIAID, NIH)  There is no drug available for the unknown diseases, pathogens and re-emergence mutants. Vincogen is focusing to solve these challenges, For example, much effort is being expended by others to produce a new flu vaccine by attacking the M2 ectodomain (M2e). M2e vaccines produced by Cytos, Acambis, Wistar Institute and Apovia Inc. are based upon protection by T helper or NK cells. There is no neutralizing antibody elicited or involved in any of these vaccines. Because Vincogen flu vaccine can display the complete tertiary structure of multimers of M2e, it elicits the exact neutralizing antibody against multimer channels structure on the surface member of flu virus. This is a more powerful tool when constructing a vaccine than by protection from T-Helper or NK cells only. The seasonal flu epitopes and M2e will be included by our patented dual expression system.

 

Gastrointestinal Diseases

There is no effective treatment or medicine for gastrointestinal diseases. One of the reasons is the obstacle of acid and proteases digestion environments in stomach, intestine and colon for protein drugs.  Vincogen protein drug can survive these harsh environments and reach the destined target site. 

1. Gastrointestinal (GI) disorders: It includes functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD), chronic gastric ulcers and colitis, afflict more than one in five Americans, particularly women.
2. Gastrointestinal Stromal Tumors: Gastrointestinal stromal tumors are a type of soft tissue sarcoma (tumor) that usually begins in cells in the wall of the stomach, intestines, or rectum. These tumors may be noncancerous or cancerous. They can affect adults, adolescents, or children.  It is estimated that around 5,000 new cases of gastrointestinal stromal tumors are diagnosed in the United States each year. This is an orphan drug candidate status.
3. Colorectal cancer: Cancer of the colon or rectum is also called colorectal cancer. In the United States, it is the fourth most common cancer in men and women.

 

Personalized medicine

Personalized medicine is the trend of future medical care.  It has reached $232 billion in USA and is projected to grow 11% annually.  The core diagnostic and therapeutic market will reach $42 billion by 2015. (12)  Vincogen is offering the solution for personalized medicine to develop the drug specifically for the patient by using his/her own diseases/pathogens as the drug template.